ABSTRACT
Background Since 2015, UK national guidelines have recommended antenatal magnesium sulfate (MgSO4) for mothers in preterm labour (<30 weeks’ gestation) to reduce the risk of cerebral palsy in the preterm baby. However, implementation of this guideline in clinical practice was slow, and MgSO4 use varied between maternity units. In 2018, the PReCePT programme, an evidence-based Quality Improvement intervention to improve use of MgSO4, was rolled-out across England. Earlier evaluation found this programme to be effective and cost-effective over the first 12 months. We extended the original evaluation to determine the programme’s longer-term impact over four years, its impact in later preterm births, impact of the COVID-19 pandemic, and to compare MgSO4 use in England, Scotland, and Wales.
Methods Quasi-experimental longitudinal study using data from the National Neonatal Research Database on babies born <30 weeks’ gestation and admitted to an NHS neonatal unit. Primary outcome was the proportion of eligible mothers receiving MgSO4, aggregated to the national level. Impact of PReCePT on MgSO4 use was estimated using multivariable linear regression. The net monetary benefit (NMB) of the programme was estimated.
Results MgSO4 administration rose from 65.8% in 2017 to 85.5% in 2022 in England. PReCePT was associated with 5.8 percentage points improvement in uptake (95%CI 2.69 to 8.86, p<0.001). Improvement was greater when including older preterm births (<34 weeks’ gestation, 8.67 percentage points, 95%CI 6.38 to 10.96, p<0.001). Most gains occurred in the first two years following implementation. PReCePT had a NMB of £597,000 with 89% probability of being cost-effective. Following implementation, English uptake appeared to accelerate compared to Scotland and Wales. There was some decline in use coinciding with the onset of the pandemic.
Conclusions The PReCePT Quality Improvement programme cost-effectively improved use of antenatal MgSO4, with benefits to the babies who have been protected from cerebral palsy.
What is already known on this topic
Antenatal magnesium sulphate (MgSO4) reduces the risk of cerebral palsy in babies born preterm.
The National PReCePT Quality Improvement Programme (NPP) effectively and cost-effectively improved use of MgSO4 in England in the first 12 months of implementation, but sustaining quality improvements over time is often challenging.
What this study adds
Using a quasi-experimental design and routinely collected, longitudinal, patient-level data, this study found that the NPP had sustained effectiveness and cost-effectiveness over four years following implementation.
Improvement may have been accelerated in England, compared to Scotland and Wales, where the NPP was not formally implemented.
How this study might affect research, practice or policy
This study demonstrates that dedicated national programmes can cost-effectively achieve improvements in perinatal care. The PReCePT model could be used as an implementation blueprint for other quality improvement initiatives in perinatal care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was jointly funded by The Health Foundation (funder's reference 557668), the National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West, core NIHR infrastructure funded: NIHR200181), and Health Innovation West of England (formerly the West of England Academic Health Science Network). The views expressed are those of the authors and not necessarily those of NHS England, NHS Improvement, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PReCePT Programme Evaluation was granted a favourable ethical opinion by the UK National Health Service Health Research Authority (HRA project ID: 260504) and the University of Bristol Faculty of Health Sciences Research Ethics Committee (FREC Ref: 84582).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Anonymised individual-level data for this study are from the NNRD. Our data sharing agreement with the NNRD prohibits sharing data extracts outside of the University of Bristol research team. The NNRD data dictionary is available online and copies of the Statistical analysis plan are available at the Open Science Framework repository (https://osf.io/be76s/).
Abbreviations
- CP
- Cerebral Palsy
- MgSO4
- Magnesium Sulphate
- NDAU
- Neonatal Data Analysis Unit
- NMB
- Net Monetary Benefit
- NNRD
- National Neonatal Research Database
- NPP
- National PReCePT Programme
- PReCePT
- Prevention of Cerebral Palsy in PreTerm Labour
- QI
- Quality Improvement
